Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07527650 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 14 to 15v6
  2. Study sites: 13 to 14v5
  3. Trial sites expanded: 10 → 13 locations
    • Primary completion pushed from Sep 2027 to Oct 2027
    v4
  4. Start date changed from estimate of Jun 2026 to May 18, 2026v3
  5. Recruitment opened
    • Trial sites expanded: 2 → 10 locations
    • Start date: May 2026 to Jun 2026
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.
Trial Details
NCT Number NCT07527650
Lead Sponsor Hanmi Pharmaceutical Company Limited
Conditions
(from sponsor)		 Type 2 Diabetes Mellitus, T2DM
Related terms Diabetes Mellitus, Type 2
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov